Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

NCT Number	NCT06234306
Lead Sponsor	Copenhagen University Hospital at Herlev Collaborators: Aarhus University Hospital, Rigshospitalet, Denmark, University of Copenhagen
Conditions	Small Bowel Adenocarcinoma
Enrollment	500 participants
Start Date	2024-01-01
Primary Completion	2033-12-31 (estimated)
Study Completion	2033-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-01-31